Showing 1181-1190 of 20397 results for "".
How To Work With Influencers Without Getting Burned
https://reachmd.com/ma-issues-index/2022-jan-feb/how-to-work-with-influencers-without-getting-burned/35133/Over the past decade, more brands have recognized the value and opportunity of working with influencersAnticipated Impacts from the COVID-19 Research Database
https://reachmd.com/programs/covid-19-frontlines/anticipated-impacts-from-the-covid-19-research-database/11515/What might we soon learn about the global COVID-19 pandemic?Increase Engagement through Transparency in Your Practice
https://reachmd.com/programs/healthcares-prescription-web-social-marketing/increase-engagement-through-transparency-in-your-practice/10174/Patients want to know WHO—not necessarily WHAT—you are, and being transparent on a personal and business level is key to bridging that gap.Assessing the Correlation Between Perianal Fistula Healing & Trough Levels of Infliximab in Children with IBD
https://reachmd.com/programs/Audioabstracts/assessing-the-correlation-between-perianal-fistula-healing-and-trough-levels-of-infliximab/10836/Some studies have found that IFX levels matter when treating fistulizing perianal Crohn’s Disease in adults, but is it the same case for children?Responding to COVID-19 in Community Practices: A Dermatologist’s Perspective
https://reachmd.com/programs/covid-19-frontlines/responding-to-covid-19-in-community-practices-a-dermatologists-perspective/11362/In order to help alleviate pressure from hospitals experiencing a high influx of patients due to COVID-19, this doctor decided to keep his doors open.Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
https://reachmd.com/programs/project-oncology/harnessing-the-immune-power-a-uniquely-designed-pd-1-inhibitor-for-esophageal-cancer/35512/Esophageal cancer is the tenth most common cancer worldwide and the sixth most prevalent cause of death due to cancer, which is why having additional treatment options for this disease is crucial.1 One available option, tislelizumab plus platinum-based chemotherapy, was recently approved by the FDAEvaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
https://reachmd.com/programs/medical-industry-feature/evaluating-efs-and-surgical-outcomes-in-resectable-nsclc-insights-from-a-clinical-trial/39813/Enhancing Lupus Nephritis Outcomes: The Potential Impact of Lower Glucocorticoid Doses
https://reachmd.com/programs/living-rheum/enhancing-lupus-nephritis-outcomes-the-potential-impact-of-lower-glucocorticoid-doses/30075/Read about recent findings on the efficacy and safety of low-dose glucocorticoids in patients with lupus nephritis.PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
https://reachmd.com/programs/heart-matters/pcsk9-inhibitors-and-statins-meta-analysis-highlights-benefit-of-combination-therapy/37594/The Regulatory Environment for the Artificial Pancreas
https://reachmd.com/programs/diabetes-discourse/the-regulatory-environment-for-the-artificial-pancreas/6500/The artificial pancreas project lead by the Juvenile Diabetes Research Foundation has made tremendous progress towards eventual outpatient clinical studies. A recent panel of experts met with the FDA and NIH to determine appropriate guidelines. What are regulatory guidelines for the artificial pan